Hammad Mohamed A, Syed Sulaiman Syed Azhar, Alghamdi Saleh, Mangi Altaf Ali, Aziz Nor Azizah, Mohamed Noor Dzul Azri
Department of Clinical Pharmacy, Faculty of Pharmacy, Sinai University, El Arish, Egypt; Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):341-346. doi: 10.1016/j.dsx.2020.04.005. Epub 2020 Apr 9.
Peripheral neuropathy (PN) is a complaint with often unidentified reasons. Some medicines, including statins therapy, are anticipated to be amongst the reasons for PN.
This study intended to assess the association of peripheral neuropathy with statins therapy amongst Type 2 diabetic patients.
At Penang General Hospital, 757 cases were categorized into two groups (564 with statins therapy and 193 without statins therapy). The diagnosis of PN was investigated retrospectively for a period of 10 years (2006-2016). Confounding risk factors as age, diabetes period, hypertension, glycemic control, other co-morbidity, and prescriptions were matched.
About 129 (22.9%) cases from 564 statins users had PN. Only 30 (15.5%) subjects had PN from 193 statins non-users. Chi-square test showed a significant variance among statins treatment cohort and statin-free cohort in the occurrence of PN (P-value: 0.001). Spearman's investigation presented a positive correlation (r: 0.078, p-value: 0.031) among statins use and PN prevalence. Binary logistic regression was statistically significant for statins therapy as a predictor of peripheral neuropathy incidence (r: 0.006, p-value: 0.027) amid diabetic patients. The relative risk of peripheral neuropathy connected with statins therapy is (RR: 1.47, 95% CI: 1.02-2.11). The excess relative risk is 47.1%. While the absolute risk (AR) is 7.3% and the number needed to harm (NNH) is 14.
The study indicated a positive association between peripheral neuropathy and statins utilization. Peripheral neuropathy was higher amongst statins users than the statins-free group.
周围神经病变（PN）常病因不明。包括他汀类药物治疗在内的一些药物被认为可能是PN的病因之一。
本研究旨在评估2型糖尿病患者中周围神经病变与他汀类药物治疗之间的关联。
在槟城总医院，757例患者被分为两组（564例接受他汀类药物治疗，193例未接受他汀类药物治疗）。对10年（2006 - 2016年）期间的PN诊断进行回顾性研究。对年龄、糖尿病病程、高血压、血糖控制、其他合并症和用药处方等混杂风险因素进行匹配。
564例使用他汀类药物的患者中约129例（22.9%）患有PN。193例未使用他汀类药物的患者中只有30例（15.5%）患有PN。卡方检验显示他汀类药物治疗组和未使用他汀类药物组在PN发生率上存在显著差异（P值：0.001）。Spearman研究表明他汀类药物使用与PN患病率之间呈正相关（r：0.078，p值：0.031）。二元逻辑回归显示，在糖尿病患者中，他汀类药物治疗作为周围神经病变发生率的预测指标具有统计学意义（r：0.006，p值：0.027）。与他汀类药物治疗相关的周围神经病变的相对风险为（RR：1.47，95%CI：1.02 - 2.11）。超额相对风险为47.1%。绝对风险（AR）为7.3%，伤害所需人数（NNH）为14。
该研究表明周围神经病变与他汀类药物使用之间存在正相关。他汀类药物使用者的周围神经病变发生率高于未使用他汀类药物的组。
